Search

Your search keyword '"Liesner, R."' showing total 493 results
Start Over Author "Liesner, R."
493 results on '"Liesner, R."'

1. One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients

Author

de Jager, Nico C.B., Bukkems, Laura H., Heijdra, Jessica M., Hazendonk, Carolien H.C.A.M., Fijnvandraat, Karin, Meijer, Karina, Eikenboom, Jeroen, Laros - van Gorkom, Britta A.P., Leebeek, Frank W.G., Cnossen, Marjon H., Mathôt, Ron A.A., Collins, P.W., Kruip, M.J.H.A., Polinder, S., Lock, J., van Moort, I., Goedhart, M.C.H.J., Coppens, M., Peters, M., Preijers, T., Brons, P., van der Meer, F.J.M., Schutgens, R.E.G., Fischer, K., Driessens, M.H.E., Zwaan, C.M., van Vliet, I., Liesner, R., Chowdary, P., and Keeling, D.

Published
2020
Full Text
View/download PDF

2. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

Author

Preijers, T., Hazendonk, H.C.A.M., Liesner, R., Chowdary, P., Driessens, M.H.E., Hart, D., Keeling, D., Laros‐van Gorkom, B.A.P., van der Meer, F.J.M., Meijer, K., Fijnvandraat, K., Leebeek, F.W.G., Collins, P.W., Cnossen, M.H., Mathôt, R.A.A., Kruip, M.J.A.H., Polinder, S., Lock, J., van Moort, I., Heijdra, J.M., Nederlof, A., de Jager, N., Coppens, M., Peters, M., Tamminga, R.Y.J., Brons, P., Eikenboom, H.C.J., Schutgens, R.E.G., Fischer, K., Zwaan, C.M., and van Vliet, I.

Published
2018
Full Text
View/download PDF

3. Inhibitor development and mortality in non‐severe hemophilia A

Author

Eckhardt, C.L., Loomans, J.I., van Velzen, A.S., Peters, M., Mauser‐Bunschoten, E.P., Schwaab, R., Mazzucconi, M.G., Tagliaferri, A., Siegmund, B., Reitter‐Pfoertner, S.E., van der Bom, J.G., Fijnvandraat, K., Kamphuisen, P.W., Peerlinck, K., Oldenburg, J., Santagostino, E., Astermark, J., Eckhardt, C.L, van Velzen, A.S, Streefkerk, N., Loomans, J.L., van Eijkelenburg, A., Jansen, A.J., Kruijt, C.C., van Tienoven, B., van Baar, A.C.G., Corten, I.W., Meijer, K., Nijziel, M.R., Dors, N., Hamulyak, K., Beckers, E., Brons, P.P., Laros‐van Gorkom, B.A.P., van Heerde, W.L., Leebeek, F., Kruip, M., Cnossen, M.H., Mauser‐Bunschoten, E., Fischer, K., Smiers, F.J., Hermans, C., Klamroth, R., Escuriola‐Ettingshausen, C., Königs, C., Petrini, P., Holmström, M., Mäkipernaa, A., Male, C., Pabinger, I., Keenan, R.D., Liesner, R., Khair, K., Yee, T.T., Hart, D.P., Rangarajan, S., Mitchell, M., Thompson, G., Haya, S., Moret, A., Cid, A.R., Jimenez‐Yuste, V., Mancuso, M.E., Mazzuconni, M.G., Santoro, C., Morfini, M., Castaman, G., Schinco, P., Rivolta, G.F., Platokouki, H., and McRae, S.

Published
2015
Full Text
View/download PDF

5. Desmopressin testing in von Willebrand disease: Lowering the burden

Author

Heijdra, Jessica M., primary, Atiq, Ferdows, additional, Al Arashi, Wala, additional, Kieboom, Quincy, additional, Wuijster, Esmee, additional, Meijer, Karina, additional, Kruip, Marieke J.H.A., additional, Leebeek, Frank W.G., additional, Cnossen, Marjon H., additional, Fijnvandraat, K., additional, Mathôt, R.A.A., additional, Polinder, S., additional, Coppens, M., additional, Tamminga, R.Y.J., additional, Meijer, K., additional, Laros‐van Gorkom, B.A.P., additional, Brons, P., additional, Schols, S.E.M., additional, van der Meer, F.J.M., additional, Eikenboom, H.C.J., additional, Schutgens, R.E.G., additional, Fischer, K., additional, Heubel‐Moenen, F., additional, Nieuwenhuizen, L., additional, Ypma, P., additional, Driessens, M.H.E., additional, Zwaan, C.M., additional, van Vliet, I., additional, Collins, P.W., additional, Liesner, R., additional, Chowdary, P., additional, Keeling, D., additional, Lock, J., additional, Hazendonk, H.C.A.M., additional, van Moort, I., additional, Preijers, T., additional, de Jager, N.C.B., additional, Goedhart, M.C.H.J., additional, Bukkems, L.H., additional, Cloesmeijer, M.E., additional, and Janssen, A., additional

Published
2022
Full Text
View/download PDF

6. Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: To WiN study

Author

Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Infection & Immunity, Heijdra, Jessica M., Al Arashi, Wala, De Jager, Nico C.B., Cloesmeijer, Michael E., Bukkems, Laura H., Zwaan, Christian M., Leebeek, Frank W.G., Mathôt, Ron A.A., Cnossen, Marjon H., Cnossen, M. H., Leebeek, F. W.G., Van Vliet, I., Fijnvandraat, K., Mathot, R. A.A., Meijer, K., Kruip, M. J.H.A., S Polinder, Polinder, Coppens, M., Tamminga, R. Y.J., Laros-Van, B. A.P., Brons, P., Schols, S. E.M., Van Der Meer, F. J.M., Eikenboom, H. C.J., Schutgens, R. E.G., Fischer, K., Heubel-Moenen, F., Nieuwenhuizen, L., Ypma, P., Driessens, M. H.E., Pw Collins, Collins, Liesner, R., Chowdary, P., Keeling, D., Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Infection & Immunity, Heijdra, Jessica M., Al Arashi, Wala, De Jager, Nico C.B., Cloesmeijer, Michael E., Bukkems, Laura H., Zwaan, Christian M., Leebeek, Frank W.G., Mathôt, Ron A.A., Cnossen, Marjon H., Cnossen, M. H., Leebeek, F. W.G., Van Vliet, I., Fijnvandraat, K., Mathot, R. A.A., Meijer, K., Kruip, M. J.H.A., S Polinder, Polinder, Coppens, M., Tamminga, R. Y.J., Laros-Van, B. A.P., Brons, P., Schols, S. E.M., Van Der Meer, F. J.M., Eikenboom, H. C.J., Schutgens, R. E.G., Fischer, K., Heubel-Moenen, F., Nieuwenhuizen, L., Ypma, P., Driessens, M. H.E., Pw Collins, Collins, Liesner, R., Chowdary, P., and Keeling, D.

Published
2022

11. One piece of the puzzle

Author

Jager, N.C.B. de, Bukkems, L.H., Heijdra, J.M., Hazendonk, C.H.C.A.M., Fijnvandraat, K., Meijer, K., Eikenboom, J., Laros-van Gorkom, B.A.P., Leebeek, F.W.G., Cnossen, M.H., Mathot, R.A.A., Kruip, M.J.H.A., Polinder, S., Lock, J., Hazendonk, H.C.A.M., Moort, I. van, Goedhart, M.C.H.J., Coppens, M., Peters, M., Preijers, T., Tamminga, R.Y.J., Brons, P., Meer, F.J.M. van der, Eikenboom, H.C.J., Schutgens, R.E.G., Fischer, K., Driessens, M.H.E., Zwaan, C.M., Vliet, I. van, Collins, P.W., Liesner, R., Chowdary, P., Keeling, D., OPTI-CLOT Grp, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Graduate School, AGEM - Digestive immunity, AGEM - Endocrinology, metabolism and nutrition, Pharmacy, Paediatric Haematology, ACS - Pulmonary hypertension & thrombosis, Amsterdam Reproduction & Development (AR&D), Pediatrics, and Hematology

Subjects
medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Population, 030204 cardiovascular system & hematology, Haemophilia, DIAGNOSIS, Gastroenterology, CLASSIFICATION, surgery, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Von Willebrand factor, Internal medicine, hemic and lymphatic diseases, Von Willebrand disease, MANAGEMENT, Medicine, education, Haemate P, Volume of distribution, education.field_of_study, biology, business.industry, FACTOR-VIII, PSN, Hematology, Perioperative, medicine.disease, NONMEM, individualized medicine, biology.protein, business, von Willebrand disease, pharmacokinetics
Abstract

Contains fulltext : 218302.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Many patients with von Willebrand disease (VWD) are treated on demand with von Willebrand factor and factor VIII (FVIII) containing concentrates present with VWF and/or FVIII plasma levels outside set target levels. This carries a risk for bleeding and potentially for thrombosis. Development of a population pharmacokinetic (PK) model based on FVIII levels is a first step to more accurate on-demand perioperative dosing of this concentrate. METHODS: Patients with VWD undergoing surgery in Academic Haemophilia Treatment Centers in the Netherlands between 2000 and 2018 treated with a FVIII/VWF plasma-derived concentrate (Haemate(R) P/Humate P(R)) were included in this study. Population PK modeling was based on measured FVIII levels using nonlinear mixed-effects modeling (NONMEM). RESULTS: The population PK model was developed using 684 plasma FVIII measurements of 97 VWD patients undergoing 141 surgeries. Subsequently, the model was externally validated and reestimated with independent clinical data from 20 additional patients undergoing 31 surgeries and 208 plasma measurements of FVIII. The observed PK profiles were best described using a one-compartment model. Typical values for volume of distribution and clearance were 3.28 L/70 kg and 0.037 L/h/70 kg. Increased VWF activity, decreased physical status according to American Society of Anesthesiologists (ASA) classification (ASA class >2), and increased duration of surgery were associated with decreased FVIII clearance. CONCLUSION: This population PK model derived from real world data adequately describes FVIII levels following perioperative administration of the FVIII/VWF plasma-derived concentrate (Haemate((R)) P/Humate P((R)) ) and will help to facilitate future dosing in VWD patients.

Published
2020

12. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency

Author

Peyvandi, F, Auerswald, G, Austin, SK, Liesner, R, Kavakli, K, Álvarez Román, MT, and Millar, CM

Abstract

Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of the associated bleeding symptoms are highly heterogeneous, adding to the difficulties of diagnosis and management. Evidence-based guidelines and reviews on factor X deficiency are generally limited to publications covering a range of rare bleeding disorders. Here we provide a comprehensive review of the literature on factor X deficiency, focusing on the hereditary form, and discuss the evolution in disease management and the evidence associated with available treatment options. Current recommendations advise clinicians to use single-factor replacement therapy for hereditary disease rather than multifactor therapies such as fresh frozen plasma, cryoprecipitate, and prothrombin complex concentrates. Consensus in treatment guidelines is still urgently needed to ensure optimal management of patients with factor X deficiency across the spectrum of disease severity.

Published
2021

24. Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients

Author

Preijers, T., Liesner, R., Hazendonk, H., Chowdary, P., Driessens, M.H.E., Hart, D.P., Laros-van Gorkom, B.A.P., Meer, F.J. van der, Meijer, K, Fijnvandraat, K., Leebeek, F.W.G., Mathôt, R.A.A., Cnossen, M.H., Preijers, T., Liesner, R., Hazendonk, H., Chowdary, P., Driessens, M.H.E., Hart, D.P., Laros-van Gorkom, B.A.P., Meer, F.J. van der, Meijer, K, Fijnvandraat, K., Leebeek, F.W.G., Mathôt, R.A.A., and Cnossen, M.H.

Abstract

Contains fulltext : 244121.pdf (Publisher’s version ) (Open Access), AIMS: Population pharmacokinetic (PK) models are increasingly applied to perform individualized dosing of factor VIII (FVIII) concentrates in haemophilia A patients. To guarantee accurate performance of a population PK model in dose individualization, validation studies are of importance. However, external validation of population PK models requires independent data sets and is, therefore, seldomly performed. Therefore, this study aimed to validate a previously published population PK model for FVIII concentrates administrated perioperatively. METHODS: A previously published population PK model for FVIII concentrate during surgery was validated using independent data from 87 children with severe haemophilia A with a median (range) age of 2.6 years (0.03-15.2) and body weight of 14 kg (4-57). First, the predictive performance of the previous model was evaluated with MAP Bayesian analysis using NONMEM v7.4. Subsequently, the model parameters were (re)estimated using a combined dataset consisting of the previous modelling data and the data available for the external validation. RESULTS: The previous model underpredicted the measured FVIII levels with a median of 0.17 IU mL(-1) . Combining the new, independent and original data, a dataset comprising 206 patients with a mean age of 7.8 years (0.03-77.6) and body weight of 30 kg (4-111) was obtained. Population PK modelling provided estimates for CL, V1, V2, and Q: 171 mL h(-1) 68 kg(-1) , 2930 mL 68 kg(-1) , 1810 mL 68 kg(-1) , and 172 mL h(-1) 68 kg(-1) , respectively. This model adequately described all collected FVIII levels, with a slight median overprediction of 0.02 IU mL(-1) . CONCLUSIONS: This study emphasizes the importance of external validation of population PK models using real-life data.

Published
2021

30. Product type and the risk of inhibitor development in nonsevere haemophilia A patients

Author

Velzen, A.S. van, Eckhardt, C.L., Peters, M., Oldenburg, J., Cnossen, M., Liesner, R., Morfini, M., Castaman, G., McRae, S., Bom, J.G. van der, Fijnvandraat, K., INSIGHT Consortium, General Paediatrics, ACS - Amsterdam Cardiovascular Sciences, Paediatric Haematology, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, and Pediatrics

Subjects
Adult, Male, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, Adolescent, animal diseases, Haemophilia A, haemophilia, Hemophilia A, Haemophilia, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Humans, Medicine, antibodies, risk factors, Major complication, Date of birth, Child, Retrospective Studies, Blood Coagulation Factor Inhibitors, business.industry, Platelets, Haemostasis and Thrombosis, Case-control study, Hematology, Odds ratio, Middle Aged, medicine.disease, Confidence interval, Increased risk, factor VIII, Child, Preschool, 030220 oncology & carcinogenesis, business, Research Paper, 030215 immunology
Abstract

Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma-derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients have shown conflicting results. We designed a case-control study to investigate the clinical and genetic risk factors for inhibitor development in nonsevere haemophilia A patients. We investigated whether the type of FVIII concentrate was associated with inhibitor development in nonsevere haemophilia A patients. This nested case-control study includes 75 inhibitor patients and 223 controls, from a source population of the INSIGHT study, including all nonsevere haemophilia A patients (FVIII:C 2-40%) that were treated with FVIII concentrates in 33 European and one Australian centre. Cases and controls were matched for date of birth and cumulative number of exposure days (CED) to FVIII concentrate. A conditional logistic regression model was used to calculate unadjusted and adjusted odds ratios. No increased risk for inhibitor development was found for any type of FVIII concentrate; either when comparing recombinant FVIII concentrates to plasma-derived FVIII concentrates (adjusted odds ratio 0 center dot 96, 95% confidence interval (CI) 0 center dot 36-2 center dot 52) or for specific types of FVIII concentrates.

Published
2020

31. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

Author

Velzen, A.S. (Alice) van, Eckhardt, C.L. (Corien L.), Peters, M.A.D. (Marjolein), Oldenburg, J., Cnossen, M.H. (Marjon), Liesner, R. (Ri), Morfini, M. (Massimo), Castaman, G. (Giancarlo), McRae, S., Bom, J.G. (Anske) van der, Fijnvandraat, K., Velzen, A.S. (Alice) van, Eckhardt, C.L. (Corien L.), Peters, M.A.D. (Marjolein), Oldenburg, J., Cnossen, M.H. (Marjon), Liesner, R. (Ri), Morfini, M. (Massimo), Castaman, G. (Giancarlo), McRae, S., Bom, J.G. (Anske) van der, and Fijnvandraat, K.

Abstract

Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma-derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients have shown conflicting results. We designed a case‒control study to investigate the clinical and genetic risk factors for inhibitor development in nonsevere haemophilia A patients. We investigated whether the type of FVIII concentrate was associated with inhibitor development in nonsevere haemophilia A patients. This nested case‒control study includes 75 inhibitor patients and 223 controls, from a source population of the INSIGHT study, including all nonsevere haemophilia A patients (FVIII:C 2–40%) that were treated with FVIII concentrates in 33 European and one Australian centre. Cases and controls were matched for date of birth and cumulative number of exposure days (CED) to FVIII concentrate. A conditional logistic regression model was used to calculate unadjusted and adjusted odds ratios. No increased risk for inhibitor development was found for any type of FVIII concentrate; either when comparing recombinant FVIII concentrates to plasma-derived FVIII concentrates (adjusted odds ratio 0·96, 95% confidence interval (CI) 0·36–2·52) or for specific types of FVIII concentrates.

Published
2020
Full Text
View/download PDF

42. Hermansky-Pudlak syndrome: infrequent bleeding and first report of Turkish and Pakistani kindreds. (Original Article)

Author

Harrison, C., Khair, K., Baxter, B., Russell-Eggitt, I., Hann, I., and Liesner, R.

Subjects
Hemorrhage -- Causes of, Albinism -- Causes of, Family and marriage, Health, Causes of
Abstract

Arch Dis Child 2002;86:297-301 Hermansky--Pudlak syndrome (HPS) is a rare disorder characterised by oculocutaneous albinism, a bleeding tendency, and lipofuscinosis. This retrospective study reviews the clinical history and haematological features [...]

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results